[1] KUMAR SK, RAJKUMAR V, KYLE RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
[2] VAN DE DONK NWCJ, PAWLYN C, YONG KL. Multiple myeloma. Lancet. 2021;397(10272):410-427.
[3] JI LL, SONG G, JIANG LM, et al. Evaluation of conditioned medium from placenta-derived mesenchymal stem cells as a storage medium for avulsed teeth: An in vitro study. Dent Traumatol. 2021;37(1):73-80.
[4] 李若林,王禹,姚奕斌,等.多发性骨髓瘤生物标志物的研究进展[J].右江医学,2021,49(11):861-864.
[5] GIALLONGO C, TIBULLO D, CAMIOLO G, et al. TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Cell Death Dis. 2019;10(10):704.
[6] GIALLONGO C, DULCAMARE I, TIBULLO D, et al. CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis. 2022;11(1):6.
[7] DENG M, YUAN H, LIU S, et al. Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression. Cytotherapy. 2019;21(1): 96-106.
[8] MATULA Z, MIKALA G, LUKÁCSI S, et al. Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells. Cancers (Basel). 2021; 13(14):3461.
[9] LIN X, YANG L, WANG G, et al. Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget. 2017;8(54):92841-92854.
[10] BÉRÉZIAT V, MAZURIER C, AUCLAIR M, et al. Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma. Cells. 2019;8(5):441.
[11] FALANK C, FAIRFIELD H, REAGAN MR. Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. Front Endocrinol (Lausanne). 2016;7:67.
[12] HOU C, SHEN L, HUANG Q, et al. The effect of heme oxygenase-1 complexed with collagen on MSC performance in the treatment of diabetic ischemic ulcer. Biomaterials. 2013;34(1):112-120.
[13] YAN S, LIU H, LIU Z, et al. CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in Myeloma Bone Disease. Cancer Med. 2020;9(2):737-744.
[14] MORRIS EV, SUCHACKI KJ, HOCKING J, et al. Myeloma Cells Down-Regulate Adiponectin in Bone Marrow Adipocytes Via TNF-Alpha. J Bone Miner Res. 2020;35(5):942-955.
[15] KASTRITIS E, TERPOS E, DIMOPOULOS MA. How I treat relapsed multiple myeloma. Blood. 2022;139(19):2904-2917.
[16] COHEN YC, ZADA M, WANG SY, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27(3):491-503.
[17] SABATTINI E, BACCI F, SAGRAMOSO C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83-87.
[18] WU D, GUO X, SU J, et al. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Biochim Biophys Acta. 2015;1853(2): 338-347.
[19] GARCIA-GOMEZ A, DE LAS RIVAS J, OCIO EM, et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 2014;5(18): 8284-8305.
[20] NOLL JE, WILLIAMS SA, PURTON LE, et al. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J. 2012;2(9):e91.
[21] MAISO P, MOGOLLÓN P, OCIO EM, et al. Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. Cancers (Basel). 2021;13(11):2542.
[22] REAGAN MR, GHOBRIAL IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012;18(2):342-349.
[23] HIDESHIMA T, ANDERSON KC. Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers (Basel). 2021;13(2):216.
[24] ZHANG L, LI K, LIU X, et al. Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats. Stem Cells Dev. 2013;22(23):3074-3086.
[25] LI Q, PANG Y, LIU T, et al. Effects of human umbilical cord-derived mesenchymal stem cells on hematologic malignancies. Oncol Lett. 2018;15(5):6982-6990.
[26] CIAVARELLA S, CASELLI A, TAMMA AV, et al. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. Stem Cells Dev. 2015;24(12):1457-1470.
[27] CHENG Q, LI X, LIU J, et al. Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a. Stem Cells Int. 2017;2017:9012152.
[28] NOLL JE, WILLIAMS SA, TONG CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163-171.
[29] LIU Z, LIU H, LI Y, et al. Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma. J Investig Med. 2020;68(1):45-51.
[30] DE VEIRMAN K, WANG J, et al. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett. 2016;377(1):17-24.
[31] DABBAH M, ATTAR-SCHNEIDER O, ZISMANOV V, et al. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation. J Leukoc Biol. 2016;100(4):761-770.
[32] TANG H, XU L, LIANG X, et al. Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways. Oncol Lett. 2018;16(5): 6608-6614.
[33] XIANG P, YEUNG YT, WANG J, et al. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. Int J Cancer. 2021;148(12):3071-3085.
[34] YAO R, HAN D, SUN X, et al. Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma. Am J Transl Res. 2017;9(11):4994-5002.
[35] JIA Y, ZHOU J, TAN TK, et al. Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. Cancer Res. 2022;82(3):406-418.
[36] FAICT S, MULLER J, DE VEIRMAN K, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8(11):105.
[37] YEN CH, HSU CM, HSIAO SY, et al. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2. Int J Mol Sci. 2020;21(18): 6723.
[38] GIULIANI N, RIZZOLI V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma. 2007;48(12):2323-2329.
[39] LOMAS OC, TAHRI S, GHOBRIAL IM. The microenvironment in myeloma. Curr Opin Oncol. 2020;32(2):170-175.
[40] ZHANG L, LEI Q, WANG H, et al. Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease. Theranostics. 2019;9(1):196-209.
[41] FAN FY, DENG R, LAI SH, et al. Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells. Oncol Lett. 2019;18(6):6536-6544.
[42] TAKEUCHI K, ABE M, HIASA M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010;5(3):e9870.
[43] GUO J, ZHAO Y, FEI C, et al. Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis. 2018;9(5):512.
[44] FAIRFIELD H, DUDAKOVIC A, KHATIB CM, et al. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype. Cancer Res. 2021;81(3):634-647.
[45] JAFARI A, FAIRFIELD H, ANDERSEN TL, et al. Myeloma-bone marrow adipocyte axis in tumour survival and treatment response. Br J Cancer. 2021;125(6):775-777.
[46] PANARONI C, FULZELE K, MORI T, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139(6):876-888.
[47] LIU H, HE J, KOH SP, et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019;11(494): eaau9087.
|